FibroBiologics, Inc. (FBLG)

FibroBiologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	8.58	6.52	3.32	1.06	0.5
Research & Development	3.92	2.37	1.15	0.52	0.67
Operating Expenses	12.51	8.89	4.47	1.58	1.17
Operating Income	-12.51	-8.89	-4.47	-1.58	-1.17
Interest Expense	-0.02	-0.15	-0.65	-0	-
Other Non Operating Income (Expenses)	-5.45	-7.45	-	-	-
Pretax Income	-17.78	-16.49	-5.12	-1.58	-1.17
Net Income	-17.78	-16.49	-5.12	-1.58	-1.17
Preferred Dividends & Other Adjustments	-	2.57	-	-	-
Net Income to Common	-17.78	-19.06	-5.12	-1.58	-1.17
Shares Outstanding (Basic)	31	28	28	9	9
Shares Outstanding (Diluted)	31	28	28	9	9
Shares Change (YoY)	11.23%	-	222.64%	-	-
EPS (Basic)	-0.57	-0.68	-0.18	-0.18	-0.13
EPS (Diluted)	-0.57	-0.68	-0.18	-0.18	-0.13
Free Cash Flow	-10.52	-6.9	-4.07	-1.41	-1.17
Free Cash Flow Per Share	-0.34	-0.24	-0.14	-0.16	-0.13
EBITDA	-12.36	-8.84	-	-	-
D&A For EBITDA	0.14	0.05	-	-	-
EBIT	-12.51	-8.89	-4.47	-1.58	-1.17

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q